73 studies found for:    Open Studies | "Vitamin K"
Show Display Options
Rank Status Study
21 Recruiting Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Condition: Atrial Fibrillation
Interventions: Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
22 Not yet recruiting Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Condition: Atrial Fibrillation
Interventions: Drug: Edoxaban;   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: ticagrelor
23 Recruiting Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib 400mg twice daily + intravenous infusion ofVit K1;   Drug: Sorafenib 400 mg twice daily + Intravenousinfusion of placebo
24 Recruiting Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Condition: Cervical Artery Dissection
Interventions: Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
25 Recruiting Aortic Calcification and Vitamin K Antagonists
Condition: Vascular Calcification
Intervention:
26 Not yet recruiting Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
Condition: Significant Bleeding Risk
Interventions: Drug: Octaplex;   Drug: Beriplex P/N (Kcentra)
27 Unknown  Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream
Condition: Metastatic Colorectal Cancer
Interventions: Device: Reconval K1 Cream;   Device: Reconval Cream
28 Recruiting Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Condition: Neoplasms
Interventions: Drug: Caffeine;   Drug: Warfarin;   Drug: Omeprazole;   Drug: Midazolam;   Drug: digoxin;   Drug: Vitamin K;   Drug: Rucaparib
29 Recruiting An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Condition: Hemorrhage
Interventions: Biological: Kcentra®;   Biological: Plasma
30 Not yet recruiting Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
31 Recruiting Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Conditions: Severe Bleeding;   Urgent Surgery
Intervention:
32 Not yet recruiting Tecarfarin Anti-Coagulation Trial (TACT)
Conditions: Thromboembolism;   Thrombosis
Interventions: Drug: Warfarin;   Drug: tecarfarin
33 Not yet recruiting COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Conditions: Stable Angina;   Unstable Angina;   STEMI;   NSTEMI;   Coronary Disease
Interventions: Device: COMBO-Stent;   Drug: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;   Device: Any drug eluting stent oder bare metal sent;   Drug: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
34 Recruiting Novel Oral Anticoagulants in Stroke Patients
Conditions: Ischemic Stroke,;   Intracranial Hemorrhage,
Intervention:
35 Recruiting Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Condition: Unsuspected Pulmonary Embolism
Intervention: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin
36 Unknown  Anti Vitamin K Therapeutic Education
Condition: Cardio-vascular Diseases
Intervention: Other: therapeutic education program
37 Recruiting Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Conditions: Atrial Fibrillation or Pulmonary Embolism;   Need of Long Term Oral Anticoagulation Therapy (OAT);   Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention: Drug: Rivaroxaban or Marcumar
38 Not yet recruiting INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
Condition: Rheumatic Heart Disease
Interventions: Drug: Rivaroxaban (15 mg);   Drug: Aspirin
39 Recruiting PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma
Conditions: Coagulation; Intravascular;   Craniocerebral Trauma;   Haemorrhage
Intervention: Procedure: Reversion
40 Recruiting Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
Conditions: Permanent Atrial Fibrillation;   Venous Thrombosis;   Pulmonary Embolism;   Anticoagulation Treatment at Least > or = to 12-month
Interventions: Drug: Rivaroxaban;   Drug: Fluindione;   Drug: Warfarin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years